Establishment Labs Hldgs saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, rising from 79 to 82.
Risk Management In The Stock Market: How Much Money To Invest Now
This proprietary rating measures technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the trailing 52 weeks matches up against that of all other stocks.
History shows that the best stocks typically have an RS Rating north of 80 as they launch their biggest price moves.
Establishment Labs Hldgs is not currently near a potential buying area. See if the stock goes on to build a chart pattern that could launch a new move.
Establishment Labs Hldgs posted 0% EPS growth last quarter, while sales growth came in at 11%. Look for the next report on or around Aug. 7.
Establishment Labs Hldgs holds the No. 44 rank among its peers in the Medical-Products industry group. Insulet, DexCom and ResMed are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
